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 Chronic diseases such as congestive heart failure (CHF) and chronic kidney 
disease (CKD) are related with multiple drug prescription which can lead to 
drug interaction. The high usage of complementary and alternative medicines 
(CAM) in Indonesians can also increase the risk for drug interaction. The 
objective of this study is to describe CAMs use and identify potential drug 
interaction with CAMs in CHF and CKD outpatients. The study is a cross 
sectional study. Data of prescribed drugs and CAMs consumed by the 
patients was collected by using medication reconciliation process. Data of 
routine CAMs and prescribed medicines were compared to identify potential 
drug interactions which were then classified based on their mechanism and 
significance. The result showed that 6,90 % of CHF patients and 25 % of 
CKD patients consumed CAMs. Potential drug interaction between the 
CAMs and the prescribed drugs was identified in 2.74% of patients 
consuming CAMs. Based on the mechanism, interaction was dominated by 
pharmacodynamics interaction (69.2%) while interaction significancy was 
various. It can be concluded that CAMs usage was more familiar in CKD 
patients compared to CHF patients. Potential drug interaction with CAMs 
was able to be identified through medication reconciliation process and 
should be taken into awareness by the healthcare team. 
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1. INTRODUCTION 
Drug Interaction is included in one of the Drug Related Problems (DRPs) which is still often seen 
nowadays in the clinical and community settings. One of the causes for the high incidence of drug interaction 
is patients receiving multiple drug prescription such as geriatric patients or patients with chronic diseases 
namely Diabetes Mellitus, hypertension, kidney failure, and heart failure. A study in a Central Public 
Hospital in Yogyakarta, Indonesia revealed a 59% of drug interaction occurence among inpatients and 69% 
in outpatients [1]. High percentage of drug interaction should lead to awareness to avoid significantly 
hazardous interactions. 
The use of complementary and alternative medicines (CAMs) such as herbs and supplements has 
been familiar among Indonesian people. Result from a national survey noticed an increase in traditional 
medicine usage for self-medication from 15.6% in 2000 to 31.7% in 2001 [2]. A following survey in 2007 
also revealed an increase of 23.1% in CAMs usage since 2000 [3]. The relationship between CAMs usage 
and drug interaction was studied by Tsai et al. which described 882 drug interaction with herbs and 
supplements, of which 240 were classified as major interaction [4].  
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High incidence of drug interaction among chronic disease patients and high CAMs usage among 
Indonesians should lead to a prevention strategy from healthcare providers. Pharmacist as one of the 
healthcare providers concerning in rational drug therapy must take the first step for this prevention strategy. 
Gathering important information of drug and CAMs usage through medication reconciliation process can be 
conducted in order to identify and prevent drug interaction in these patients which eventually could prevent 
medication errors caused by drug interaction [5]. This could be a beneficial support to physicians who 
usually meet difficulty in screening and detection process of drug interactions in patients’ drug list [6]. 
This study is aimed to describe CAMs use and identify potential drug interaction between prescribed 
drugs and between CAMs with the prescribed drugs in congestive heart failure (CHF) and chronic kidney 
disease (CKD) outpatients through medication reconciliation process as the first step in preventing drug 
interaction. 
 
 
2. RESEARCH METHOD 
This study was conducted through a cross sectional design and has pass ethical clearance. Subjects 
recruited were outpatients visiting one of a private hospital in Special District of Yogyakarta, Indonesia from 
August to October 2014. Patients were enrolled into the study if they were diagnosed with either congestive 
heart failure or chronic renal disease and were willing to participate, verified by signing the inform consent 
provided by the researcher. 
Medication reconciliation process was then conducted to the selected patients. Patients that met the 
inclusion criteria were interviewed to collect and gather up data of medication and CAMs usage (defined as 
herbs and dietary supplements) wether prescribed or non-prescribed by their doctor. Patients were requested 
to explain the name, dose, frequency, how, and when they consume the medication or CAMs. 
Identification of potential drug interaction was done by comparing medication and CAMs used by 
the patients routinely before their visit to the hospital with medication obtained from the doctor. Literature 
study was held to verify the potential interactions, using mainly Drug Interaction Facts by Tatro (2010) and 
Stockley’s Drug Interaction. 
 
 
3. RESULTS AND ANALYSIS 
3.1. Distribution of Patients 
Patients selected for the study was divided into two subjects based on their main diagnosis which are 
Chronic Kidney Disease (CKD) patients or Congestive Heart Failure (CHF) patients. Seventy three patients 
met the inclusion criteria from both subjects. Distribution of patients’ diagnosis can be seen in Figure 1. 
 
 
 
 
Figure 1. Distribution of Patients 
 
 
From 73 patients, 29 patients (40%) were diagnosed with CHF while the rest of 44 patients (60%) 
were diagnosed with CKD. CHF and CKD patients are examples of chronic disease patients with a relatively 
high prevalence in Indonesia, especially in The Special District of Yogyakarta. Based on the National 
Primary Health Research (Riset Kesehatan Dasar) published in 2013 by The Indonesian Ministry of Health, 
Yogyakarta had the highest prevalence of diagnosed CHF patients with a percentage of 0.25% compared with 
the other provinces [7]. Meanwhile, the prevalence of CKD patients in Yogyakarta was also included in the 
high prevalence group (0.3%) with East Nusa Tenggara, South Sulawesi, Lampung, West Java, Central Java 
and East Java [7]. 
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3.2. Drug Combination and CAMs usage 
Data of drug combination and CAMs usage in patients’ especially chronic disease patients is 
essential to obtain a brief description on potential drug interactions. Table 1 list the number of drug 
combination in patients with CHF and CKD. 
 
 
Table 1. Drug Combination in Patients 
Drug combination ∑ CHF patients ∑ CKD patients Total Percentage (%) 
≤ 3 combination 8 - 8 11 
4 – 6 combination 21 29 50 68.5 
> 6 combination - 15 15 20.5 
Total 29 44 73 100 
 
 
As seen in Table 1, the majority of patients were being prescribed with 4 to 6 combination of drugs 
(68.5%). While drug combination could have beneficial effect on treating various diseases, the use of 
irrational drug combination (including CAMs) has been known to increase the risk of potential hazardous 
effect such as detrimental drug interactions [8]. Therefore rational drug combination should be a concern in 
healthcare providers in order to give the patient the optimum drug therapy. 
Chronic kidney disease patients were identified with more drug combinations than CHF patients. 
This might occur because of various complications seen in patients with CKD such as anemia, electrolyte 
imbalance, osteodystrophy, etc whereas each complication has its own therapy [9]. This is different from 
CHF patients which usually are not accompanied with many complications. As for CAMs usage, Figure 2 
describes the difference between the CHF and CKD patients. 
 
 
 
 
Figure 2. CAMs usage in CHF and CKD patients 
 
 
Based on Figure 2, CKD patients were more familiar with CAMs usage compared with CHF 
patients (25% versus 6.9%). The high usage of CAMs in CKD patients in this study is similar with the results 
seen from a study in Thailand where half of the CKD patients included in the study used herbs and dietary 
supplements. These patients were mostly using herbs and supplements with a purpose of maintaining their 
well-being. Friends and family recommendation was the main reason to try, while perceived benefits of using 
the CAMs was mostly the reason to continue consuming them [10],[11]. 
 
3.3. Potential Drug Interaction 
Potential drug interactions were identified by comparing drugs and/or CAMs consumed routinely 
with the new drugs prescribed by the doctor at the time of hospital visit. Drug interaction was then classified 
as pharmacokinetic and pharmacodynamic interaction based on the mechanism of the interactions. 
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Significancy of interaction as one of the important parameters in making follow up decisions was determined 
by classification from Tatro’s Drug Interaction Facts (2010). The result can be seen in Table 2. 
 
 
Table 2. Potential Drug Interactions in CHF and CKD patients 
Drug A Drug B 
Interaction Mechanism 
Significancy 
Ph. Kinetic Ph. dynamic 
A. CHF patients 
Acetosal Bisoprolol 1  4 
Digoxin Captopril 2  4 
Digoxin Lisinopril 5  4 
Digoxin Spironolakton 7  2 
Furosemid Digoxin  13 1 
Furosemid Captopril  2 3 
Warfarin Turmeric Acid  1 5 
Clopidogrel Fish Oil  1 2 
B. CKD patients 
Acetosal Vitamin B12 2  3 
Acetaminophen Furosemid 2  5 
Nifedipine Diltiazem 1  3 
Omeprazole Vitamin B12 2  5 
Bisoprolol Diltiazem 2  2 
Bisoprolol Clonidine  6 1 
Furosemid Captopril  5 3 
Bisoprolol Nifedipine  7 4 
Acetosal Captopril  1 2 
Acetosal Clopidogrel  1 1 
Captopril Epoetin Alpha  15 Unknown 
Captopril Potassium  1 Unknown 
Captopril Irbesartan  1 Unknown 
Total of patients 24 54  
Percentage (%) 30.8 69.2  
Ph.kinetic: Pharmacokinetic, Ph.dynamic: Pharmacodynamic 
 
 
As shown in Table 2, potential drug interactions identified in CHF and CKD patients mostly had 
pharmacodynamic mechanism. This type of interaction refers to drugs or substances that interact in the same 
receptor system, target of action or physiology system which then contributes to an additive (sinergistic) or 
antagonistic effect while pharmacokinetic interactions usually cause an increase or decrease of drug 
concentration in the blood eventually leading to toxic or subtherapeutic effect [12]. If compared with 
pharmacokinetic interactions, pharmacodynamic interactions usually needs a much deeper comprehension on 
the mechanism of action for the drugs or substance to interact [13]. Therefore predicting effect of this type of 
interactions may require several considerations. 
When analyzing potential drug interactions in patients, consideration should be given mostly on 
types of interactions that are clinically significant which will possibly have significant effect on the patients. 
In this study, significance of the interaction can be seen by the number of significance level (last column in 
Table 2), where the smaller the number, the more significant. This should be the basis for healthcare provider 
(especially the pharmacist) to determine the best intervention in order to prevent detrimental effect on the 
patients due to drug interactions. The significance level of 1 indicates an interaction which is capable in 
causing permanent damage and death to patients [14]. Potential interactions identified in this level were 
furosemide with digoxin, bisoprolol with clonidine, and acetosal (aspirin) with clopidogrel. Given a high 
number of cases (13 cases), co-administration of furosemide with digoxin is a common prescription in CHF 
patients. Both drugs are essential to maintain CHF patient stability and has been recommended for heart 
failure patients with reduced ejection fraction [15]. The interaction between the two drugs is capable on 
increasing the risk of digoxin toxicity due to hypokalemia which can lead to effects such as arrhythmia. 
Many studies have shown digoxin toxicity leading to hospitalization among CHF patients prescribed with 
both digoxin and diuretic agents. A high incidence of hospitalization is mostly seen in CHF patients who 
receive more than one diuretic agent in combination with digoxin. Therefore combining digoxin with several 
diuretic agents must be avoided, while co-administration of digoxin with one diuretic agent such as 
furosemide can be handled by potassium monitoring (to determine risk of hypokalemia) and adding 
potassium supplement (to prevent hypokalemia) [14],[16]. 
Related to CAMs consumption in CHF and CKD patients, there were 2 cases (2.74%) of patients 
consuming turmeric acid and fish oil were identified with pharmacodynamics interaction with the other 
prescribed drugs. Turmeric acid has a potential interaction with warfarin which is an anticoagulant agent 
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usually prescribed in CHF patients with diagnose of atrial fibrillation in order to reduce the risk for 
thromboembolic event [17]. Turmeric acid is known to have an in vitro effect in the inhibition of platelet 
activating factor (PAF) and platelet aggregation therefore increasing the risk of bleeding in patients 
consuming anticoagulant. Documentation for this type of interaction has not yet been well established and 
there could be variation in pharmacological effect due to inconsistency of the herb potency itself [18]-[20]. A 
significance level of 5 for this potential interaction indicates a minor clinical significance; hence, the patient 
must still be monitored for risk of bleeding which is the most common side effect of warfarin. Awareness 
must be raised since warfarin is included in drugs with a narrow therapeutic index where risk of toxicity 
could increase or could become less effective if consumed with herbs [21]. 
While the potential interaction between turmeric acid and warfarin was stated as minor, another 
interaction with CAMs identified in this study had a significance level of 2. One patient prescribed with 
clopidogrel also consumed fish oil which (based on literature) could lead to an interaction between both. Fish 
oil is known to potentiate pharmacological effect of anticoagulant and other drugs which have effect on 
platelets and thrombin such as clopidogrel. Therefore this supplement has been widely used (and commonly 
prescribed by doctors) for patients with or at risk for cardiovascular diseases. A study of fish oil 
supplementation in diabetes patients using low dose aspirin shown that co-administration revealed a greater 
reduction of aggregation of platelet compared to aspirin alone. Despite the benefit of fish oil supplementation 
in patients also receiving antiplatelets or anticoagulants, consideration must be given specifically to patients 
with high risk of bleeding such as patients in plan for surgery or patients who appears with signs of even mild 
bleeding [22]-[24]. 
 
 
4. CONCLUSION 
Complementary and alternative medicines (CAMs) usage was more familiar in CKD patients 
compared to CHF patients. Potential drug interactions with CAMs were identified (although in a small 
number; 2.74%) as pharmacodynamic mechanism through medication reconciliation process and should be 
taken into awareness by the healthcare team according to the significance level of interaction besides other 
prescribed drug interactions which are commonly seen in chronic disease patients. 
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